downgraded at Stifel from Buy to Hold,
downgraded at Auriga from Buy to Hold. $28 price target. Industry still faces macro headwinds.
(HES - Get Report)
downgraded at Deutsche from Buy to Hold, Deutsche Bank said. $62 price target. Company has a very aggressive spending program in 2012.
downgraded at Stifel from Buy to Hold, Stifel Nicolaus said. Valuation call.
upgraded at Baird to Outperform, Robert Baird said. $60 price target. Stock likely to trade above Roche's hostile bid.
Illinois Tool Works
upgraded at BofA/Merrill from Underperform to Buy, Bank of America/Merrill Lynch said. $64 price target. Company is cutting costs and deserves a higher price multiple.
upgraded at BofA/Merrill from Neutral to Buy, Bank of America/Merrill Lynch said. Valuation call, based on a $20 price target.
upgraded at Leerink from Market Perform to Outperform, Leerink Swann said. Nextgen sequencing is an attractive growth area.
(NFLX - Get Report)
upgraded at Citigroup to Buy from Neutral, Citigroup said. $130 price target. Strong quarter and positive guidance.
downgraded at Jefferies to Hold from Buy, Jefferies said. $58.50 price target. Lower assumed processing and gathering volumes at Enogex.
downgraded at Goldman to Sell. $18 price target. Pricing trends are better in the commercial lines.
rated new Neutral at Goldman. $22 price target. Company has limited earnings upside potential.
downgraded at JP Morgan to Neutral. Estimates also cut, given a lower net interest margin and a difficult sales environment.
upgraded at Canaccord from Hold to Buy. $50 price target. Guidance will likely prove to be conservative.
downgraded at Goldman from Neutral to Sell. $25 price target. Company is leveraged to weaker financial services and European demand.
downgraded at KBW to Underperform, Keefe, Bruyette & Woods said. Valuation call, based on a $21 price target. Estimates also cut.
upgraded at Earlybird to Buy, Earlybird Capital said. $30 price target. End-market demand is improving and the company has operating leverage.